ClinicalTrials.gg
RecruitingNCT06966362Updated Aug 31, 2026

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

A Phase 4 interventional study of Motivation-Phase Varenicline and Motivation-Phase Nicotine Mini-Lozenge in Veterans, Tobacco Use Disorder and Cigarette Smoking, sponsored by VA Office of Research and Development. Recruiting at 4 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies testing varenicline in Tobacco Use Disorder — 5 open to participants now, 5 under way, 1 of them phase 3. Varenicline · Tobacco Use Disorder.

Planned enrollment
9th of 74
400 · median 113
Started
2026
the only one that year
Phase 4
19 of 74
2 open now
Registered
73rd of 74
by date

Among the 74 studies testing varenicline in Tobacco Use Disorder, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 19 in phase 4, and was the 73rd registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 74 studies testing varenicline in Tobacco Use Disorder are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing varenicline in Tobacco Use Disorder, or all of them as a file.
02

Study summary

In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.

Read the detailed description

Evidence-based smoking cessation treatments can double smoking abstinence rates, yet these treatments are underused by the millions of Veterans who smoke. One reason for this is that the great majority of people who smoke are not ready to make a quit attempt when cessation treatment is offered (70-90%). An important public health goal is to increase engagement of people not ready to quit smoking in highly effective treatment that prepares them to make quit attempts and ultimately achieve abstinence (i.e., Motivation-phase treatment; MPT). MPT typically combines smoking reduction counseling with nicotine replacement therapy (NRT). Although offering NRT Motivation-phase treatment (NRT MPT) in healthcare settings increases the reach of tobacco treatment, such interventions only weakly affect long-term abstinence. It is vital that the investigators develop more effective MPTs that increase quit attempts and quitting success in people not ready to quit. Varenicline, the most effective single agent smoking cessation pharmacotherapy, holds great promise as an intervention for people who are not ready to make a quit attempt. The investigators propose that MPT will be markedly more effective if it involves the use of varenicline (vs. NRT) because it will more effectively reduce smoking reward, affective withdrawal, and tonic craving. Initial evidence suggests that varenicline increases quitting motivation in those not ready to quit, but the extant studies have not 1) directly evaluated varenicline effectiveness in this population and 2) compared varenicline MPT with NRT MPT, the current standard treatment for those not ready to make a quit attempt. The goal of this study is to evaluate whether varenicline MPT is especially effective and cost-effective relative to NRT MPT, in Veterans who are willing to reduce but not quit smoking. This study will compare the use of varenicline MPT vs. NRT MPT on: biochemically verified point-prevalence abstinence at 1 year (primary outcome), quit attempts, and cessation treatment use.

This study is a 2-group randomized controlled trial that will enroll 400 adults from three geographically diverse VA hospitals who smoke 5 cigarettes/day and do not want to quit smoking in the next 30 days but are willing to cut down. Participants will be randomized to one of two 12-week MPT groups: (1) varenicline, or (2) NRT (2 milligrams (mg) mini-lozenges). All participants will receive 5 phone counseling sessions focused on smoking reduction during the 12-week MPT. Any participants who decide to try quitting will receive smoking cessation treatment involving continued use of their assigned study medication and cessation counseling.

03

Conditions studied

  • Veterans
  • Tobacco Use Disorder
  • Cigarette Smoking
  • Tobacco Dependence

Keywords

  • Varenicline
  • Tobacco use disorder
  • Veterans
  • Quit attempts
  • Cigarette smoking
  • Motivation phase treatment
  • Nicotine replacement therapy
  • Smoking reduction
  • Smoking abstinence
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Report smoking an average of 5 or more cigarettes daily for the previous 6 months
  • Not ready to set a quit date in the next 30 days but willing to cut down on their smoking
  • Able to read, write, and speak English
  • Be medically eligible to use study medications (nicotine replacement therapy (NRT) or varenicline)
  • If female, use an approved method of while using study medication
  • Be a Veteran

Exclusion criteria

Exclusion Criteria:

  • Unable to give informed, voluntary consent to participate
  • Current use of any pharmacotherapy for smoking cessation
  • Use of non-cigarette tobacco products as primary form of tobacco use
  • Incarceration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Motivation-Phase Varenicline

    Varenicline use during pre-quit phase of smoking treatment for participants who are interested in cutting down on their smoking.

    Drug: Motivation-Phase Varenicline · Drug: Cessation-Phase Varenicline · Behavioral: Motivation-Phase Counseling · Behavioral: Cessation-Phase Counseling

  • Active comparator
    Motivation-Phase Nicotine Mini-Lozenge

    NRT mini-lozenge use during pre-quit phase of smoking treatment for participants who are interested in cutting down on their smoking.

    Drug: Motivation-Phase Nicotine Mini-Lozenge · Drug: Cessation-Phase Combination Nicotine Replacement Therapy (NRT) · Behavioral: Motivation-Phase Counseling · Behavioral: Cessation-Phase Counseling

Interventions

  • DrugVareniclineStudies of VareniclineVarenicline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Varenicline reduction dosing will start when participants initiate Motivation-phase treatment: 0.5 milligrams (mg) once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the duration of the 12-week reduction regimen.

    Also known as: Chantix

  • DrugNicotine Chewing GumStudies of Nicotine Chewing GumNicotine Chewing Gum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NRT mini-lozenge reduction dosing will start when participants initiate Motivation-phase treatment: 2-milligrams (mg) mini-lozenges in place of cigarettes (5-15/day).

    Also known as: Nicorette

  • DrugCessation-Phase Combination Nicotine Replacement Therapy (NRT)

    Combination NRT (nicotine patch + nicotine mini-lozenge) cessation dosing will begin on the target quit day: if smoking \>10 cigarettes/day = 8 weeks of 21-milligrams (mg), 2 weeks of 14-mg, and 2 weeks of 7-mg nicotine patches; if smoking 10 cigarettes/day = 10 weeks of 14-mg and 2 weeks of 7-mg nicotine patches. All participants will receive 2 or 4 mg mini-lozenge for the 12-week cessation period (9/day, 1 piece every 1-2/hours).

    Also known as: Nicorette, Nicoderm

  • DrugVareniclineStudies of VareniclineVarenicline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Varenicline cessation dosing will start one week prior to their target quit date (TQD): 0.5 milligrams (mg) once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the remainder of the 12-week cessation regimen.

    Also known as: Chantix

  • BehavioralMotivation-Phase Counseling

    All participants receive motivation-phase counseling. Motivation-phase counseling involves 5, 10-15-minute counseling calls. The counselor will work with participants on smoking control skills selected by the participant, such as avoidance of smoking cues, reducing smoking heaviness/contexts, developing urge coping skills, or finding support from friends and family. Counseling will emphasize setting realistic and achievable smoking control goals. Counseling will also emphasize competence and self-efficacy, which will be linked to success in smoking control.

  • BehavioralCessation-Phase Counseling

    All participants who enter cessation treatment will be offered 4, 10-15-minute counseling calls. The first counseling session involves pre-quit preparation, and can occur any time before the target quit day. The other 3 counseling calls will be scheduled for 1 day, 1 week, and 4 weeks after the target quit date. Cessation counseling will be based on treatment guidelines and will review instructions for when to start cessation medication, the timing of the quit day (relative to medication start), and medication adherence. Counseling will involve problem solving and skill development.

06

What researchers measure

Primary outcomes

  1. 7-day point prevalence abstinence

    Participants who report 7-day point-prevalence abstinence from cigarettes at the 6 month follow-up will mailed a saliva collection kit that will test cotinine and anabasine to validate self-reported abstinence from combusted tobacco.

    Time frame: 6 months post-study entry

Secondary outcomes

  1. Making a quit attempt lasting 24 hours

    Making a quit attempt lasting at least 24 hours by 6 and 12 months; coded as binary (0 or 1).

    Time frame: 6 and 12 months post-study entry

  2. Cessation treatment entry

    Entering cessation treatment; coded as binary (0 or 1)

    Time frame: 6 months post-study entry

  3. Biochemically confirmed 7-day point-prevalence abstinence

    Participants who report 7-day point-prevalence abstinence from cigarettes at the 12 month follow-up will mailed a saliva collection kit that will test cotinine and anabasine to validate self-reported abstinence from combusted tobacco.

    Time frame: 12 months post-study entry

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Deidentified dataset will be shared upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2030, 46 months after the start.

Of 38 non-industry phase 4 interventional studies under Tobacco Use Disorder, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 46 months is above that.

Counting every sponsor, half of 38 studies reached it within 41 months; a quarter within 30 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 11, 2025
StartActual
Aug 17, 2026
Primary completionEst.
Jun 28, 2030
CompletionEst.
Jun 28, 2030
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06966362
Responsible party
Sponsor
First posted
May 11, 2025
Start date
Aug 17, 2026
Primary completion
Jun 28, 2030 (estimated)
Completion
Jun 28, 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

Jessica M Cook, PhD
Contact
Jessica.Cook2@va.gov
(608) 256-1901
Elana G Brubaker, MSW BS
Contact
elana.brubaker@va.gov
(608) 256-1901 ext. 17854
Jessica Megan Cook, PhD
principal investigator · William S. Middleton Memorial Veterans Hospital, Madison, WI
Neal M Doran, PhD
principal investigator · VA San Diego Healthcare System, San Diego, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion